New partnership to probe the complexities of the brain
Posted by
19-Jul-2013
The 1990s was dubbed ‘The Decade of the Brain’ and saw huge strides made in the understanding of neurological function. We learned a lot about how the brain works – and what is happening when problems arise.
Around the same time, the Human Genome Project was beginning to deepen scientists’ appreciation of the role of genetics in health and disease.
We have come a long way in a short time. Yet the brain’s unparalleled complexity means that there is still much to learn. Indeed, despite the progress seen in recent decades, the underlying causes of many serious neurological disorders remain unclear.
Learning more about how the brain develops, the role of genetics, and how this knowledge can be translated into new therapies is an exciting challenge.
Better together
UCB’s “open innovation” approach to drug discovery reflects our commitment to building collaborations and partnerships where our combined expertise can deliver the treatments that patients with serious diseases need.
We are, as ever, Inspired by Patients. Driven by Science.
This is the spirit behind our latest research alliance with the Lieber Institute for Brain Development (LIBD), a private not-for-profit academic research organisation hosted in the Johns Hopkins University School of Medicine.
LIBD focuses on understanding the neurodevelopmental origins of schizophrenia and related developmental brain disorders and translating this understanding into improving the lives of affected individuals.
Our strategic collaboration will harness the respective expertise of UCB and LIBD for the discovery of new drug candidates for treating patients suffering from cognitive impairment.
It combines UCB’s world-class Central Nervous System research teams with LIBD’s unique understanding of basic genetic and molecular mechanisms of developmental brain disorders. The ambitious challenge of bringing new therapies to patients is best tackled together.
Around the same time, the Human Genome Project was beginning to deepen scientists’ appreciation of the role of genetics in health and disease.
We have come a long way in a short time. Yet the brain’s unparalleled complexity means that there is still much to learn. Indeed, despite the progress seen in recent decades, the underlying causes of many serious neurological disorders remain unclear.
Learning more about how the brain develops, the role of genetics, and how this knowledge can be translated into new therapies is an exciting challenge.
Better together
UCB’s “open innovation” approach to drug discovery reflects our commitment to building collaborations and partnerships where our combined expertise can deliver the treatments that patients with serious diseases need.
We are, as ever, Inspired by Patients. Driven by Science.
This is the spirit behind our latest research alliance with the Lieber Institute for Brain Development (LIBD), a private not-for-profit academic research organisation hosted in the Johns Hopkins University School of Medicine.
LIBD focuses on understanding the neurodevelopmental origins of schizophrenia and related developmental brain disorders and translating this understanding into improving the lives of affected individuals.
Our strategic collaboration will harness the respective expertise of UCB and LIBD for the discovery of new drug candidates for treating patients suffering from cognitive impairment.
It combines UCB’s world-class Central Nervous System research teams with LIBD’s unique understanding of basic genetic and molecular mechanisms of developmental brain disorders. The ambitious challenge of bringing new therapies to patients is best tackled together.
Leave a Comment